

PAR/CS/NSE/2023-24/11

To,
The Manager
Listing department,
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block-G,
Bandra Kurla Complex, Bandra (E),
Mumbai- 400 051
Maharashtra

Date: 01/06/2023**Symbol - PAR, ISIN: INE04LG01015**

Subject: Investors Presentation

Ref.: Regulation 30 read with Schedule III of SEBI (Listing Obligations And
Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

With reference to above captioned subject and pursuant Regulation 30 read with Schedule III of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015, we hereby attached our latest Investors Presentation.


You are requested to kindly take note on your record.

Yours Faithfully

For PAR DRUGS AND CHEMICALS LIMITED

(Mr. Falgun V. Savani)**Managing Director****DIN: 00198236**

Encl: As above





Q4-FY23/FY23 Earnings Presentation

Company Overview




Company Overview




- Promoted by Mr. Falgun Savani and Mr. Jignesh Savani, Par Drugs and Chemicals Limited (PDCL) was founded in 1982 and is engaged in the development and manufacturing of APIs.
- The Company today manufactures 25 different products and all the requisite grades as available in the market. The product portfolio presently comprises of 15 APIs and 10 Fine Chemicals which are marketed domestically and exported.
- Currently, the company owns and operates a manufacturing facility at Bhavnagar in Gujarat with an annual capacity of 9,700 MT.
- The company is the largest manufacturer of Magnesium Hydroxide, Sucralfate and Magnesium Trisilicate in India.
- Company's key customers include Essential Drugs Company Ltd., Pfizer Ltd., United Phosphorus Ltd., Cipla Ltd., etc.
- PDCL exports its products to approximately 16 countries, including Germany, the United Kingdom, Bangladesh, Iran, and U.A.E etc.
- APIs, also known as "bulk drugs" or "bulk actives" are the principal ingredient used in making finished dosages in the form of capsules, tablets, liquid, or other forms of dosage, with the addition of other APIs or inactive ingredients.

Operational Revenues (INR Mn)



Business Mix (FY23)





Diversified Portfolio: The company manufactures the entire range of products in the Antacid segment. The product portfolio presently comprises 15 APIs and 10 Fine Chemicals which are marketed domestically and exported.



Global Presence: The Company is operating both in domestic and export markets. The export products are to approximately 16 countries, including Germany, United Kingdom, Bangladesh, Iran, and U.A.E, Indonesia, Japan, South Korea, etc.



Experienced Promoters: Led by qualified and experienced Promoters and key managerial personnel, who we believe have extensive knowledge and understanding of the APIs business environment and have the expertise and vision to organically scale up the business.



Robust Chemistry Capabilities: A research driven Company with R&D efforts focused on developing processes and achieving process improvements and production cost efficiencies.



Diversified Customer base: Catering to more than 250 customers through dealers/agents worldwide.




Established Sales and distribution network: Comprising of more than 40 dealers and distribution network is spread globally comprising of 13 agents.



Cash Rich Company: The company is a net debt free and generates free cash flow. They plan expansions through internal accruals.

The image features a background of financial documents with a bar chart and a pie chart. A pair of glasses is visible in the upper right. A large blue circle on the left contains the text 'FINANCIAL & OPERATIONAL HIGHLIGHTS'. A yellow circle is positioned in the center. The bar chart shows monthly data from February to December with values ranging from 10.85 to 31.08. The pie chart shows segments with values 22 and 29.

FINANCIAL & OPERATIONAL HIGHLIGHTS



Q4-FY23/FY23 Financial & Operational Highlights

Q4-FY23 Financial Highlights

Revenue INR 245 Mn	EBITDA INR 53 Mn	EBITDA Margin 21.63%
PAT INR 34 Mn	PAT Margin 13.88%	Diluted EPS INR 2.80

FY23 Financial Highlights

Revenue INR 957 Mn	EBITDA INR 182 Mn	EBITDA Margin 19.02%
PAT INR 113 Mn	PAT Margin 11.81%	Diluted EPS INR 9.21

Operational Highlights

- Overall, sales growth for the quarter was 11% whereas for the FY23 sales grew by around 27%
- Sales growth in domestic market was 15% for the quarter and 34% for FY23
- The export market growth was 8% in Q4-FY23 and 11% in FY23
- The PAT margin on sales increased from 11% in Q4-FY22 to 14% for the quarter
- Sales growth was achieved by using only 3 plants as the company is working on the restructuring of the old plant to increase production capacity
- Generated net cash inflow of around INR 42 Mn in FY23 after payment of capital expenditures of old plant renovation



Q4-FY23/FY23 Financial Overview



Quarterly Income Statement (IND-AS)

Income Statement (INR Mn)	Q4-FY23	Q4-FY22	Y-o-Y	Q3-FY23	Q-o-Q
Income from Operations	245	221	10.9%	229	7.0%
Total Expenses	192	176	9.1%	197	(2.5)%
EBITDA	53	45	17.8%	32	65.6%
<i>EBITDA Margins (%)</i>	<i>21.63%</i>	<i>20.36%</i>	<i>127 Bps</i>	<i>13.97%</i>	<i>766 Bps</i>
Finance Cost	0	1	NA	0	NA
Depreciation	8	9	(11.1)%	7	14.3%
Other Income	0	1	NA	0	NA
Profit Before Tax	45	36	25.0%	25	80.0%
Tax	11	12	(8.3)%	6	83.3%
Profit after tax	34	24	41.7%	19	78.9%
<i>PAT Margins (%)</i>	<i>13.88%</i>	<i>10.86%</i>	<i>302 Bps</i>	<i>8.30%</i>	<i>558 Bps</i>
Diluted EPS (INR)	2.80	1.97	42.1%	1.52	84.2%

Annual Income Statement (IND-AS)

Income Statement (INR Mn)	FY23	FY22	Y-o-Y
Income from Operations	957	751	27.4%
Total Expenses	775	588	31.8%
EBITDA	182	163	11.7%
<i>EBITDA Margins(%)</i>	<i>19.02%</i>	<i>21.70%</i>	<i>(268) Bps</i>
Finance Cost	1	5	(80.0)%
Depreciation	32	33	(3.0)%
Other Income	2	2	NA
Profit Before Tax	151	127	18.9%
Tax	38	35	8.6%
Profit after tax	113	92	22.8%
<i>PAT Margins (%)</i>	<i>11.81%</i>	<i>12.25%</i>	<i>(44) Bps</i>
Diluted EPS (INR)	9.21	7.49	23.0%

Historical Income Statement

Income Statement (INR Mn)	FY20	FY21	FY22	FY23
Income from Operations	558	608	751	957
Total Expenses	464	447	588	775
EBITDA	94	161	163	182
<i>EBITDA Margins (%)</i>	<i>16.85%</i>	<i>26.48%</i>	<i>21.70%</i>	<i>19.02%</i>
Finance Cost	8	7	5	1
Depreciation	27	28	33	32
Other Income	1	2	2	2
Profit before Extra Ordinary Items	60	128	127	151
Extraordinary items	-	19	-	-
Profit Before Tax	60	147	127	151
Tax	12	31	35	38
Profit after tax	48	116	92	113
<i>PAT Margins (%)</i>	<i>8.60%</i>	<i>19.08%</i>	<i>12.25%</i>	<i>11.81%</i>
Diluted EPS (INR)	7.75	18.87	7.49	9.21

Balance Sheet


EQUITIES & LIABILITIES (INR Mn)	FY21	FY22	FY23
Shareholder Funds	522	599	712
(A) Equity Share Capital	61	123	123
(B) Reserves & Surplus	461	476	589
Non-current Liabilities	82	39	36
(A) Long Term borrowings	44	-	-
(B) Deferred Tax Liabilities (net)	34	35	35
(C) Long term Provisions	4	4	1
Current Liabilities	160	149	141
(A) Short term borrowings	32	-	-
(B) Trade Payables	67	107	81
(C) Other Current Liabilities	25	8	20
(D) Short term Provisions	36	34	40
GRAND TOTAL - EQUITIES & LIABILITES	764	787	889

ASSETS (INR Mn)	FY21	FY22	FY23
Non Current Assets	352	351	394
(A) Fixed Assets			
(i) Tangible Assets	299	341	385
(ii) Capital work-in-progress	45	2	2
(B) Non Current Investments	0	0	0
(C) Other Non Current Assets	8	8	7
Current Assets	412	436	495
(A) Inventories	30	47	54
(B) Trade Receivables	125	185	170
(C) Cash & cash equivalents	212	163	222
(D) Short Term Loans & Advances	0	0	1
(E) Current Tax Assets	34	32	41
(F) Other Current Assets	11	9	7
GRAND TOTAL – ASSETS	764	787	889


Operational Revenue (INR Mn)




EBITDA (INR Mn) & EBITDA Margins (%)




PAT (INR Mn) & PAT Margins (%)




RoCE & RoE




Net Debt to Equity Ratio (x)



Net Worth (INR Mn)



Stock Market Performance (as on 31st March, 2023)




Price Data (31st March, 2023)

INR

Face Value	10.0
Market Price	140.0
52 Week High/Low	199.7/128.4
Market Cap (Mn)	1,722.6
Equity Shares Outstanding (Mn)	12.3
1 Year Avg Trading Volume ('000)	19.0

Shareholding Pattern as on 31st March, 2023



Par Drugs and Chemicals Limited:

The above Presentation with slides have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company. This Presentation has been prepared based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of or any omission from, this Presentation is expressly excluded. All actions and statements made herein or otherwise shall be subject to the applicable laws and regulations as amended from time to time. There is no representation that all information relating to the context has been taken care off in the presentation and neither we undertake any obligation as to the regular updating of the information as a result of new information, future events or otherwise. We will accept no liability whatsoever for any loss arising directly or indirectly from the use of, reliance of any information contained in this presentation or for any omission of the information. The information shall not be distributed or used by any person or entity in any jurisdiction or countries were such distribution or use would be contrary to the applicable laws or Regulations. It is advised that prior to acting upon this presentation independent consultation / advise may be obtained and necessary due diligence, investigation etc may be done at your end. You may also contact us directly for any questions or clarifications at our end. This presentation contain certain statements of future expectations and other forward-looking statements, including those relating to our general business plans and strategy, our future financial condition and growth prospects, and future developments in our industry and our competitive and regulatory environment. The Company's actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections. In addition to statements which are forward looking by reason of context, the words 'may, will, should, expects, plans, intends, anticipates, believes, estimates, predicts, potential or continue and similar expressions identify forward looking statements. Actual results, performances or events may differ materially from these forward-looking statements including the plans, objectives, expectations, estimates and intentions expressed in forward looking statements due to a number of factors, including without limitation future changes or developments in our business, our competitive environment, telecommunications technology and application, and political, economic, legal and social conditions in India. It is cautioned that the foregoing list is not exhaustive This presentation is not being used in connection with any invitation of an offer or an offer of securities and should not be used as a basis for any investment decision.

Valorem Advisors Disclaimer:

Valorem Advisors is an Independent Investor Relations Management Service company. This Presentation has been prepared by Valorem Advisors based on information and data which the Company considers reliable, but Valorem Advisors and the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded. Valorem Advisors also hereby certifies that the directors or employees of Valorem Advisors do not own any stock in personal or company capacity of the Company under review.

For further details, please feel free to contact our Investor Relations Representatives:



Mr. Anuj Sonpal

Valorem Advisors

Tel: +91-22-4903-9500

Email: pardrugs@valoremadvisors.com



Thank
You